Login
Companies $XERS
$16.49 -$0.21 (1.26%) After hours
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc.

xerispharma.com

What Do They Do?

Sells prescription medicines and develops injectable drug candidates for people with endocrine and neurological diseases.

How Do They Make Money?

Sells its products mainly to wholesalers or a specialty pharmacy, with product sales counted when those buyers obtain the goods; collaboration and technology-partnership revenue is earned under contract terms.

revenue
SegmentShareRevenue
Product revenue, net
Sold outright

97%
FY2022: 99%
Royalty, contract and other revenue
3.0%
FY2022: 0.9%

Who Are Their Customers?

Xeris sells mainly to wholesalers or a specialty pharmacy, which resell products to retail pharmacies or patients; it also works with payors, group purchasing organizations and healthcare providers on rebates and discounts.

Do Revenues Turn Into Profits?

Yes. It kept less than a cent of every revenue dollar as net income in FY2025.

Operating income, FY2025
9% of revenue
▲ Turned profitable vs FY2024 (−$33.6M, −17%)
Net income, FY2025
0% of revenue
▲ Turned profitable vs FY2024 (−$54.8M, −27%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +44%
vs $74.4M in Q3 FY2025
Net income
▲ +1718%
vs $621K in Q3 FY2025
Product revenue, net share of revenue vs 99.6% in Q3 FY2025
  • Aug 6, 2026 Tightened full-year revenue guidance Set the 2026 revenue outlook at $385 million to $390 million.
  • Jun 30, 2026 CEO John Shannon appointed board chair The board appointed Shannon to serve as Chairperson, effective July 1, 2026.

Growing. Revenue grew 5.9x in 4 years, from $49.6M in FY2021 to $291.8M in FY2025, about 56% a year.

Pipeline development The older report described the levothyroxine candidate as an early-stage program with a dose-finding study planned; the latest report says the dose-finding study is complete and a pivotal trial is planned.

Revenue over time
Product revenue, net Royalty, contract and other revenue Gvoke Keveyis Recorlev
$500M$250M$0

Who Do They Compete With?

Competes with Corcept Therapeutics, Teva Pharmaceutical Industries, Recordati Rare Diseases, HRA Pharma, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, Stero Therapeutics, Lundbeck, Amphastar, Zealand Pharma, Fresenius Kabi, Torrent Pharmaceuticals, Cycle Pharmaceuticals, and Rising Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support